Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Iasonos

The PI3Kδ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Hematological Oncology

English

ME-401, a NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-Kinase P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B-Cell LYMPHOID MALIGNANCIES

Hematological Oncology

English

Related publications

Safety and Efficacy of Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2015

English

Transcend CLL 004: Minimal Residual Disease After Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematological Oncology

English

Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Cytometry Part B - Clinical Cytometry

English

Outcomes With Bruton Tyrosine Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Progression on Venetoclax

Hematological Oncology

English

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

English

A Phase I/Ii Study of Rituximab and Etanercept in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

English

R-Dhap Is Effective in Fludarabine-Refractory Chronic Lymphocytic Leukemia

English

Small Lymphocytic Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology

English

Safety and Early Data From a Phase Ii Trial of Pembrolizumab (Pem) and Entinostat (Ent) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (Hl) and Follicular Lymphoma (Fl)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Iasonos

The PI3Kδ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)

ME-401, a NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-Kinase P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B-Cell LYMPHOID MALIGNANCIES

Related publications

Safety and Efficacy of Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant

Transcend CLL 004: Minimal Residual Disease After Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Outcomes With Bruton Tyrosine Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Progression on Venetoclax

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase I/Ii Study of Rituximab and Etanercept in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

R-Dhap Is Effective in Fludarabine-Refractory Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Safety and Early Data From a Phase Ii Trial of Pembrolizumab (Pem) and Entinostat (Ent) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (Hl) and Follicular Lymphoma (Fl)